{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:05:28Z","timestamp":1783915528602,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Youth Project of Suzhou Municipal Health Commission","award":["KJXW2023079"],"award-info":[{"award-number":["KJXW2023079"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LYY19H280006"],"award-info":[{"award-number":["LYY19H280006"]}]},{"name":"the Clinical Research Project of Wujieping Medical Foundation","award":["320.6750.2024-18-11"],"award-info":[{"award-number":["320.6750.2024-18-11"]}]},{"name":"Special Research Project of Hospital Pharmacy of Zhejiang Pharmaceutical Society","award":["2023ZYY03"],"award-info":[{"award-number":["2023ZYY03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05302-z","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:01:20Z","timestamp":1776229280000},"page":"14455-14468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse event profiles of fenofibrate and gemfibrozil: a retrospective comparative study and literature synthesis"],"prefix":"10.1007","volume":"399","author":[{"given":"Jing","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Yang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"5302_CR1","doi-asserted-by":"publisher","unstructured":"Agha RA, Mathew G, Rashid R, Kerwan A, Al-Jabir A, Sohrabi C, Franchi T, Nicola M, Agha M, TITAN Group et al (2025) Transparency in the reporting of artificial intelligence \u2013 the TITAN guideline. Premier J Sci 10:100082. https:\/\/doi.org\/10.70389\/PJS.100082","DOI":"10.70389\/PJS.100082"},{"key":"5302_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1567-5688(15)30001-5","volume":"19","author":"C Aguiar","year":"2015","unstructured":"Aguiar C, Alegria E, Bonadonna RC et al (2015) A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl 19:1\u201312","journal-title":"Atheroscler Suppl"},{"key":"5302_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19072148","author":"M Araki","year":"2018","unstructured":"Araki M, Nakagawa Y, Oishi A et al (2018) The peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) agonist pemafibrate protects against diet-induced obesity in mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19072148","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5302_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1067\/mcp.2000.108507","volume":"68","author":"J Backman","year":"2000","unstructured":"Backman J (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68(2):122\u2013129","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"5302_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/00007890-199405820-00018","volume":"58","author":"P Boissonnat","year":"1994","unstructured":"Boissonnat P, Salen P, Guidollet J et al (1994) The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients[J]. Transplantation 58(2):245\u2013247","journal-title":"Transplantation"},{"issue":"24","key":"5302_CR6","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM et al (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 41(24):2313\u20132330","journal-title":"Eur Heart J"},{"issue":"12","key":"5302_CR7","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/ndt\/15.12.1993","volume":"15","author":"N Broeders","year":"2000","unstructured":"Broeders N, Knoop C, Antoine M et al (2000) Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 15(12):1993\u20139","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"5302_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1053\/j.ajkd.2018.12.043","volume":"74","author":"L Brown","year":"2019","unstructured":"Brown L, Luciano A, Pendergast J et al (2019) Predictors of net acid excretion in the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis 74(2):203\u2013212","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"5302_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","volume":"32","author":"MJ Chapman","year":"2011","unstructured":"Chapman MJ, Ginsberg HN, Amarenco P et al (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32(11):1345\u201361","journal-title":"Eur Heart J"},{"issue":"12","key":"5302_CR10","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","volume":"121","author":"EY Chew","year":"2014","unstructured":"Chew EY, Davis MD, Danis RP et al (2014) The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes. Ophthalmology 121(12):2443\u20132451","journal-title":"Ophthalmology"},{"issue":"6a","key":"5302_CR11","doi-asserted-by":"publisher","first-page":"3c","DOI":"10.1016\/j.amjcard.2006.11.016","volume":"99","author":"MH Davidson","year":"2007","unstructured":"Davidson MH, Armani A, Mckenney JM et al (2007) Safety considerations with fibrate therapy. Am J Cardiol 99(6a):3c\u201318c","journal-title":"Am J Cardiol"},{"issue":"2","key":"5302_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","volume":"54","author":"TM Davis","year":"2011","unstructured":"Davis TM, Ting R, Best JD et al (2011) Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study[J]. Diabetologia 54(2):280\u2013290","journal-title":"Diabetologia"},{"issue":"6","key":"5302_CR13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1592\/phco.29.6.744","volume":"29","author":"DL Dixon","year":"2009","unstructured":"Dixon DL, Williams VG (2009) Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy 29(6):744\u2013748","journal-title":"Pharmacotherapy"},{"key":"5302_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/diseases11040140","author":"MV Ezhov","year":"2023","unstructured":"Ezhov MV, Arutyunov GP (2023) Effectiveness and safety of fenofibrate in routine treatment of patients with hypertriglyceridemia and metabolic syndrome. Diseases. https:\/\/doi.org\/10.3390\/diseases11040140","journal-title":"Diseases"},{"issue":"2","key":"5302_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.clinthera.2008.02.004","volume":"30","author":"S Fazio","year":"2008","unstructured":"Fazio S (2008) Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clin Ther 30(2):294\u2013306","journal-title":"Clin Ther"},{"issue":"Suppl C","key":"5302_CR16","doi-asserted-by":"publisher","first-page":"C2","DOI":"10.1093\/eurheartj\/suw009","volume":"18","author":"R Ferrari","year":"2016","unstructured":"Ferrari R, Aguiar C, Alegria E et al (2016) Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl 18(Suppl C):C2-c12","journal-title":"Eur Heart J Suppl"},{"issue":"3","key":"5302_CR17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/biology3030536","volume":"3","author":"A Frazier-Wood","year":"2014","unstructured":"Frazier-Wood A, Wojczynski M, Borecki I et al (2014) Genetic risk scores associated with baseline lipoprotein subfraction concentrations do not associate with their responses to fenofibrate. Biology 3(3):536\u2013550","journal-title":"Biology"},{"issue":"10","key":"5302_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrcardio.2013.117","volume":"10","author":"AM Gotto Jr.","year":"2013","unstructured":"Gotto AM Jr., Moon JE (2013) Pharmacotherapies for lipid modification: beyond the statins. Nat Rev Cardiol 10(10):560\u201370","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"5302_CR19","doi-asserted-by":"publisher","first-page":"7872","DOI":"10.1007\/s12035-019-01649-y","volume":"56","author":"CG Gottschalk","year":"2019","unstructured":"Gottschalk CG, Roy A, Jana M et al (2019) Activation of peroxisome proliferator-activated receptor-\u03b1 increases the expression of nuclear receptor related 1 protein (Nurr1) in dopaminergic neurons. Mol Neurobiol 56(11):7872\u20137887","journal-title":"Mol Neurobiol"},{"issue":"1","key":"5302_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","volume":"27","author":"VH Haase","year":"2013","unstructured":"Haase VH (2013) Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 27(1):41\u201353","journal-title":"Blood Rev"},{"issue":"5","key":"5302_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/01.mca.0000224406.60573.8e","volume":"17","author":"M Haim","year":"2006","unstructured":"Haim M, Benderly M, Boyko V et al (2006) Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy. Coron Artery Dis 17(5):455\u201361","journal-title":"Coron Artery Dis"},{"issue":"9500","key":"5302_CR22","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial[J]. Lancet 366(9500):1849\u20131861","journal-title":"Lancet"},{"key":"5302_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0663-8","author":"K Kim","year":"2017","unstructured":"Kim K, Kleinman HK, Lee H-J et al (2017a) Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-017-0663-8","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"5302_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0663-8","volume":"12","author":"K Kim","year":"2017","unstructured":"Kim K, Kleinman HK, Lee HJ et al (2017b) Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis 12(1):113","journal-title":"Orphanet J Rare Dis"},{"key":"5302_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ijcard.2016.11.245","volume":"228","author":"CE Leonard","year":"2017","unstructured":"Leonard CE, Brensinger CM, Bilker WB et al (2017) Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics. Int J Cardiol 228:761\u2013770","journal-title":"Int J Cardiol"},{"key":"5302_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-017-0033-5","author":"Y Li","year":"2017","unstructured":"Li Y, Yang C, Zhang L et al (2017) MicroRNA-210 induces endothelial cell apoptosis by directly targeting PDK1 in the setting of atherosclerosis. Cell Mol Biol Lett. https:\/\/doi.org\/10.1186\/s11658-017-0033-5","journal-title":"Cell Mol Biol Lett"},{"issue":"6","key":"5302_CR27","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1111\/jcmm.15012","volume":"24","author":"T Li","year":"2020","unstructured":"Li T, Hu SM, Pang XY et al (2020) The marine\u2010derived furanone reduces intracellular lipid accumulation in vitro by targeting LXR\u03b1 and PPAR\u03b1. J Cell Mol Med 24(6):3384\u20133398","journal-title":"J Cell Mol Med"},{"issue":"3","key":"5302_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1507\/endocrj.EJ24-0286","volume":"72","author":"J Li","year":"2025","unstructured":"Li J, Xie J, Han Y et al (2025) A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database. Endocr J 72(3):273\u2013283","journal-title":"Endocr J"},{"issue":"7347","key":"5302_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature10146","volume":"473","author":"P Libby","year":"2011","unstructured":"Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347):317\u2013325","journal-title":"Nature"},{"issue":"1","key":"5302_CR30","first-page":"39","volume":"55","author":"J Lipscombe","year":"2001","unstructured":"Lipscombe J, Lewis GF, Cattran D et al (2001) Deterioration in renal function associated with fibrate therapy[J]. Clin Nephrol 55(1):39\u201344","journal-title":"Clin Nephrol"},{"issue":"3","key":"5302_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1053\/j.gastro.2019.05.057","volume":"157","author":"Y Luo","year":"2019","unstructured":"Luo Y, Xie C, Brocker CN et al (2019) Intestinal PPAR\u03b1 protects against colon carcinogenesis via regulation of methyltransferases DNMT1 and PRMT6. Gastroenterology 157(3):744-759.e4","journal-title":"Gastroenterology"},{"key":"5302_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1425617","volume":"15","author":"K Mao","year":"2024","unstructured":"Mao K, Chen P, Sun H et al (2024) Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS). Front Pharmacol 15:1425617","journal-title":"Front Pharmacol"},{"issue":"20","key":"5302_CR33","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.jacc.2019.10.009","volume":"74","author":"GA Mensah","year":"2019","unstructured":"Mensah GA, Roth GA, Fuster V (2019) The global burden of cardiovascular diseases and risk factors: 2020 and beyond. J Am Coll Cardiol 74(20):2529\u20132532","journal-title":"J Am Coll Cardiol"},{"key":"5302_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0755-3","author":"J Murai","year":"2018","unstructured":"Murai J, Nishizawa H, Otsuka A et al (2018) Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation. Cardiovasc Diabetol. https:\/\/doi.org\/10.1186\/s12933-018-0755-3","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"5302_CR35","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.2337\/dc11-1811","volume":"35","author":"JC Mychaleckyj","year":"2012","unstructured":"Mychaleckyj JC, Craven T, Nayak U et al (2012) Reversibility of fenofibrate therapy\u2013induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 35(5):1008\u20131014","journal-title":"Diabetes Care"},{"issue":"4","key":"5302_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG (2016) Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 118(4):547\u2013563","journal-title":"Circ Res"},{"issue":"11","key":"5302_CR37","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1194\/jlr.R071233","volume":"57","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A (2016) Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res 57(11):1953\u20131975","journal-title":"J Lipid Res"},{"issue":"12","key":"5302_CR38","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/bmjqs-2015-004411","volume":"25","author":"G Ogrinc","year":"2016","unstructured":"Ogrinc G, Davies L, Goodman D et al (2016) SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf 25(12):986\u2013992","journal-title":"BMJ Qual Saf"},{"issue":"1","key":"5302_CR39","first-page":"74","volume":"18","author":"KA Perkins","year":"2016","unstructured":"Perkins KA, Karelitz JL, Michael VC et al (2016) Initial evaluation of fenofibrate for efficacy in aiding smoking abstinence. Nicotine Tob Res 18(1):74\u20138","journal-title":"Nicotine Tob Res"},{"issue":"11","key":"5302_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2019.100081","volume":"12","author":"S Principe","year":"2019","unstructured":"Principe S, Benfante A, Calzetta L et al (2019) Age does not affect the efficacy of anti-IL-5\/IL-5R in severe asthmatics. World Allergy Organ J 12(11):100081","journal-title":"World Allergy Organ J"},{"issue":"25","key":"5302_CR41","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO et al (2020) Global burden of cardiovascular diseases and risk factors, 1990\u20132019. J Am Coll Cardiol 76(25):2982\u20133021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"5302_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021508","volume":"8","author":"A Sahebkar","year":"2019","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Katsiki N et al (2019) Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials[J]. BMJ Open 8(11):e021508","journal-title":"BMJ Open"},{"key":"5302_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091218","author":"MB Shah","year":"2022","unstructured":"Shah MB (2022) Inhibition of CYP2C8 by acyl glucuronides of gemfibrozil and clopidogrel: pharmacological significance, progress and challenges. Biomolecules. https:\/\/doi.org\/10.3390\/biom12091218","journal-title":"Biomolecules"},{"issue":"9","key":"5302_CR44","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1111\/bph.13055","volume":"172","author":"IG Sharina","year":"2015","unstructured":"Sharina IG, Sobolevsky M, Papakyriakou A et al (2015) The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies. Br J Pharmacol 172(9):2316\u201329","journal-title":"Br J Pharmacol"},{"issue":"34","key":"5302_CR45","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1093\/eurheartj\/ehab841","volume":"43","author":"L Tokg\u00f6zo\u011flu","year":"2022","unstructured":"Tokg\u00f6zo\u011flu L, Libby P (2022) The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J 43(34):3198\u20133208","journal-title":"Eur Heart J"},{"key":"5302_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041188","author":"Y Tomita","year":"2020","unstructured":"Tomita Y, Fu Z, Wang Z et al (2020) Long-acting FGF21 inhibits retinal vascular leakage in in vivo and in vitro models. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21041188","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5302_CR47","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/0091270010366446","volume":"51","author":"LR Whitfield","year":"2011","unstructured":"Whitfield LR, Porcari AR, Alvey C et al (2011) Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol 51(3):378\u201388","journal-title":"J Clin Pharmacol"},{"key":"5302_CR48","doi-asserted-by":"crossref","unstructured":"Wolska A, Lo L, Sviridov DO et al (2020) A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides. Sci Transl Med 12(528)","DOI":"10.1126\/scitranslmed.aaw7905"},{"key":"5302_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.119922","author":"P Wu","year":"2020","unstructured":"Wu P, Wang L, Li W et al (2020) Construction of vascular graft with circumferentially oriented microchannels for improving artery regeneration. Biomaterials. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.119922","journal-title":"Biomaterials"},{"key":"5302_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.844350","author":"W Xiao","year":"2022","unstructured":"Xiao W, Ma L, Shang Y et al (2022) Cardiac-related lesions in newly diagnosed patients with acute leukemia: a Chinese population-based real-world study. Front Med (Lausanne). https:\/\/doi.org\/10.3389\/fmed.2022.844350","journal-title":"Front Med (Lausanne)"},{"key":"5302_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1595027","volume":"12","author":"F Xu","year":"2025","unstructured":"Xu F, Li LC, Chen MM et al (2025) Antithrombotic management in an elderly CABG patient with nephrotic syndrome: a case report. Front Cardiovasc Med 12:1595027","journal-title":"Front Cardiovasc Med"},{"key":"5302_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.913977","volume":"9","author":"Z Yang","year":"2022","unstructured":"Yang Z, Yang K, Shi J et al (2022) The association between remnant cholesterol and the estimated 10-year risk of a first hard cardiovascular event. Front Cardiovasc Med 9:913977","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"5302_CR53","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/hmg\/ddz290","volume":"29","author":"ZA Yavarow","year":"2020","unstructured":"Yavarow ZA, Kang HR, Waskowicz LR et al (2020) Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia[J]. Hum Mol Genet 29(2):286\u2013294","journal-title":"Hum Mol Genet"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05302-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05302-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05302-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:43:38Z","timestamp":1783914218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05302-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5302"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05302-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on a public FAERS database developed for everyone and does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}